NASDAQ
27.02.26 | 21:59
12,570 US-Dollar
-7,16 % -0,970
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Guggenheim raises Phathom stock price target to $25 on revenue beat | 1 | Investing.com | ||
| Do | Phathom outlines $320M-$345M 2026 revenue guidance as company targets operating profitability | 1 | Seeking Alpha | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Do | Stifel reiterates Buy on Phathom stock, keeps $28 price target | 3 | Investing.com | ||
| Do | Phathom Q4 2025 slides: 217% revenue growth, profitability in sight | 3 | Investing.com | ||
| Do | Phathom Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| Do | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.01. | Phathom Pharmaceuticals: Stifel bekräftigt "Buy"-Rating nach starkem Umsatzausblick | 7 | Investing.com Deutsch | ||
| 15.01. | Phathom Pharmaceuticals stock maintains Buy rating at Stifel on strong revenue outlook | 4 | Investing.com | ||
| 14.01. | Cantor Fitzgerald reiterates Overweight rating on Phathom stock at $29 | 2 | Investing.com | ||
| 14.01. | Cantor Fitzgerald bestätigt "Overweight" für Phathom und sieht 86 % Kurspotenzial | 6 | Investing.com Deutsch | ||
| 08.01. | Phathom Pharma Shows Sales Strength, Targets 2026 Profitability | 5 | Benzinga.com | ||
| 08.01. | Phathom Pharmaceuticals prices $130 million public offering | 12 | Investing.com | ||
| 08.01. | Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 07.01. | Phathom Pharmaceuticals announces public offering of common stock | 3 | Investing.com | ||
| 07.01. | Phathom Pharma plans public offering after reporting preliminary 2025 results | 1 | Seeking Alpha | ||
| 07.01. | Phathom Pharmaceuticals kündigt nach Kursrallye öffentliches Aktienangebot an | 5 | Investing.com Deutsch | ||
| 07.01. | Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 07.01. | Phathom Pharmaceuticals reports Preliminary Q4 results | 2 | Seeking Alpha | ||
| 07.01. | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | 203 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| 07.01. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIKING THERAPEUTICS | 28,340 | -1,19 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| BIOCRYST PHARMACEUTICALS | 7,342 | -0,92 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| IMMUNITYBIO | 8,228 | -0,75 % | ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally | 2025 Sales Momentum: ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an approximately 700% increase year-over-year... ► Artikel lesen | |
| MICROBOT MEDICAL | 2,038 | -0,29 % | H.C. Wainwright bestätigt Rating für Microbot Medical nach Adoption durch Klinik | ||
| CYTOKINETICS | 53,50 | +0,94 % | Cytokinetics, Incorporated: Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update | MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,426 | -1,44 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| CAPRICOR | 23,300 | -1,48 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,240 | -0,96 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,280 | -1,38 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer | CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,500 | -1,32 % | Johnson Fistel, PLLP: Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses | San Diego, California--(Newsfile Corp. - February 19, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,100 | -2,26 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 116,00 | +0,87 % | Palvella Therapeutics Inc.: Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations | Primary endpoint met with statistically significant improvement (mean change of +2.13; p Achieved statistical significance on pre-specified key secondary endpoint (p 95% of trial participants aged... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 13,200 | -4,35 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at Upcoming Investor Conferences | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences:
TD Cowen 46th Annual... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,190 | 0,00 % | Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 6,500 | +3,17 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential... ► Artikel lesen |
Das Unternehmen PHATHOM PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -7,16 % bei einem Aktienkurs von 12,570 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.